Several PD-1 inhibitors are approved by the FDA for treating various solid tumors. The most common and widely used include pembrolizumab (Keytruda) and nivolumab (Opdivo). Other approved PD-1 inhibitors include cemiplimab (Libtayo), dostarlimab (Jemperli), retifanlimab (Zynyz), and toripalimab (Loqtorzi).
___
And.....
*Keytruda: ..Merck
*Opdivo: .....Bristol Myers Squibb
*Libtayo: .....Regeneron
*Jemperli: ..GSK
*Zynyz: .......Incyte Corporation
*Loqtorzi: ...Coherus BioSciences, Inc